<table cellpadding="0" cellspacing="0" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="85.5pt"></col>
<col width="418.5pt"></col>
<tbody>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="bold">Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease <content stylecode="italics">[see </content>
<content stylecode="italics">
<linkhtml href="#LINK_cadf7348-9bc5-4b60-8189-ae8732913bb7">Clinical Pharmacology (12.3)</linkhtml> ]</content>, resulting in decreased opioid efficacy or withdrawal symptoms in patients physically dependent on methadone.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>If concomitant use is necessary, consider dosage reduction of methadone hydrochloride tablets until stable drug effects are achieved. Monitor patients for respiratory depression and sedation at frequent intervals. If a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor is discontinued, follow patients for signs of opioid withdrawal and consider increasing the methadone hydrochloride tablets dosage until stable drug effects are achieved.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Examples</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g. ketoconazole), protease inhibitors (e.g., ritonavir), fluconazole, fluvoxamine, Some selective serotonin reuptake inhibitors (SSRIs) (e.g., sertraline, fluvoxamine)</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="bold">Inducers of CYP3A4, CYP2B6, CYP2C19, or CYP2C9</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, or</paragraph>
<paragraph>CYP2C9 inducers can decrease the plasma concentration of methadone <content stylecode="italics">[see <linkhtml href="#LINK_cadf7348-9bc5-4b60-8189-ae8732913bb7">Clinical Pharmacology (12.3)</linkhtml>]</content>, resulting in decreased efficacy or onset of withdrawal symptomsin patients physically dependent on methadone. These effects could be more pronouncedwith concomitant use of drugs that can induce multiple CYP enzymes.After stopping a CYP3A4, CYP2B6, CYP2C19, or CYP2C9 inducer, as the effects ofthe inducer decline, the methadone plasma concentration can increase <content stylecode="italics">[see <linkhtml href="#LINK_cadf7348-9bc5-4b60-8189-ae8732913bb7">Clinical Pharmacology (12.3)</linkhtml>]</content>, which could increase or prolong both the therapeutic effects andadverse reactions, and may cause serious respiratory depression, sedation, or death.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>If concomitant use is necessary, consider increasing the methadone hydrochloride tablets dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal. If a CYP3A4, CYP2B6, CYP2C19, or CYP2C9 inducer is discontinued, consider methadone hydrochloride tablets dosage reduction and monitor for signs of respiratory depression and sedation.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Rifampin, carbamazepine, phenytoin, St. John’s Wort, Phenobarbital</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="bold">Benzodiazepines and other Central Nervous System (CNS) Depressants</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients closely for signs of respiratory depression and sedation <content stylecode="italics">[see <content stylecode="italics">
<linkhtml href="#LINK_7648ac5b-9ec0-4fdb-9459-036946ad6821">Warnings </linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#LINK_7648ac5b-9ec0-4fdb-9459-036946ad6821">and Precautions (5.6)</linkhtml>
</content>]</content>.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="bold">Potentially Arrhythmogenic Agents</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Pharmacodynamic interactions may occur with concomitant use of methadone and potentially arrhythmogenic agents or drugs capable of inducing electrolyte disturbances (hypomagnesemia, hypokalemia).</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Monitor patients closely for cardiac conduction changes.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Drugs known to have potential to prolong QT interval: Class I and III antiarrhythmics, some neuroleptics and tricyclic antidepressants, and calcium channel blockers. Drugs capable of inducing electrolyte disturbances: Diuretics, laxatives, and, in rare cases, mineralocortocoid hormones.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="bold">Serotonergic Drugs</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome <content stylecode="italics">[see <content stylecode="italics">
<linkhtml href="#LINK_2059cb3c-44bc-4c90-91b5-5a4fb6e6de8e">Warnings and</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#LINK_2059cb3c-44bc-4c90-91b5-5a4fb6e6de8e">Precautions (5.8)</linkhtml>
</content>].</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue methadone hydrochloride tablets if serotonin syndrome is suspected.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="bold">Monoamine Oxidase Inhibitors (MAOIs)</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>MAOI interactions with opioids may manifest as serotonin syndrome <content stylecode="italics">[see <linkhtml href="#LINK_2059cb3c-44bc-4c90-91b5-5a4fb6e6de8e">Warnings and Precautions (5.8)</linkhtml>] </content>or opioid toxicity (e.g., respiratory depression, coma) <content stylecode="italics">[see <linkhtml href="#LINK_ecae70a2-dc5c-44fb-be88-70135d9931d3">Warnings and Precautions (5.2)</linkhtml>].</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>The use of methadone hydrochloride tablets is not recommended for patients taking MAOIs or within 14 days of stopping such treatment.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="bold">Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>May reduce the analgesic effect of methadone hydrochloride tablets and/or precipitate withdrawal symptoms.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Avoid concomitant use.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>butorphanol, nalbuphine, pentazocine, buprenorphine</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="bold">Muscle Relaxants</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Methadone may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Monitor patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of methadone hydrochloride tablets and/or the muscle relaxant as necessary.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="bold">Diuretics</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="bold">Anticholinergic Drugs</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Monitor patients for signs of urinary retention or reduced gastric motility when</paragraph>
<paragraph>Methadone hydrochloride tablets are used concomitantly with anticholinergic drugs.</paragraph>
</td>
</tr>
</tbody>
</table>